Aptadel Therapeutics’ Post

The pharmaceutical landscape is witnessing a continuous improvement in the design of small molecule drugs with an increasing number of small molecules receiving FDA approval. We're witnessing the fruition of smarter drug design strategies in the industry. #AIDrugDiscovery #DrugDiscovery

🤝 #Productive #partnerships between #biotech and #CDMOs are key to the #success of joint #drug projects, whether in #development or commercial #manufacturing. 👉 At this year's #BioIntegrates2024, a panel discussion will explore facets of this fundamental topic. Neil Jones, Chief Commercial Officer at CDMO Aenova, gives 3 #tips for productive partnerships today. Listen in!

Excited to announce that I will be attending Bioeurope Spring, one of the most prominent biotech partnering conferences! Looking forward to connecting with industry leaders, exploring innovative collaborations, and staying up-to-date with the latest trends in the life sciences sector. If you'll be there too, I would love to meet up and discuss potential opportunities. See you at #BioEuropeSpring! #MilliporeCTDMO #Drugconjugate #smallmolecule #HPAPI #linkerpayload"

Last week was very full for NeoVentures globally! Gregory and Ximena participated in partnering meetings at #BioEurope Spring in Barcelona in three areas. ☑ New partnerships for aptamer projects for NVB Canada ☑ Pilot projects for Aptamarker projects with NVB Europe ☑ Kick-off of round A investment for NVB Europe (10M €) We were very pleased with the quality and enthusiasm of everyone we met with. This was a highly productive conference for us, and the food in Barcelona is always wonderful. Cole Drake participated virtually in the #Aptamer Conference in Oxford. We sponsored travel budgets for students globally to attend this meeting in person. We learned a lot from advances in #aptamerscience by leading labs (and friends) throughout the world. We remain convinced that our reinvention of #aptamerdevelopment with our #neomer libraries represents the next generation of aptamers (to learn more please visit www.neoaptamers.com). Jeremie Thiblet presented the NVB Europe opportunity to over 70 investors and companies in Paris. Our pitch was well received and we will be following up with several groups. To learn more about this opportunity please visit www.neoventures-eu.com It is exciting to see and work with the #renewedenergy around aptamers that is building with our many success stories. A key success has been our ability to develop aptamers as #drugdelivery vectors by selecting them for the capacity to induce #endocytosis. Another area of extensive discussion has been our successful application of aptamers in affinity columns for purification of small #molecules as well as very large entities.

Check out the progress made for this cross-industry collaboration!

Join Ed Harnaga from Pfizer at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends

CONTENT NEWS FROM REPO4EU REPO4EU has first results on mechanism-based #biomarkers on an epidemiological level collaborating with the BBMRI-ERIC member, Estonian #Biobank, and cellular proof-of-concept for a new #network #pharmacology concept in #cancer. The REPO-HYPER II trial in mechanism-based subtype in #resistant #hypertension is scheduled to start in 2024. Reimbursement for innovative theranostics repurposing several registered drugs remains a challenge. We have submitted our application for a feasibility study to convert REPO4EU into REPOSystem, a permanent European research infrastructure. And last not least, our RexPo‘24 conference in Munich will kick off July 3rd. Abstracts can be submitted as of last week.

🌟 Exciting News Alert! 🌟 Thrilled to announce that Zuzanna Szklarz and Dominika Kulpińska will be representing ClinMark at the prestigious Swiss Biotech Day! 🇨🇭 Join us at our stand for engaging discussions, networking opportunities, and to explore the latest advancements in clinical research. See you there! #SwissBiotechDay #ClinMark #ClinicalResearch #Networking #IndustryInsights

Don’t miss out on our dedicated track for Strategy and Dealmaking at the Fierce Biotech Summit on Sept 30th – Oct 1st. ➡️Click here to learn more https://ow.ly/BWJR50SzHck Explore the dynamics of partnerships, collaborations, and investments in biotech. Examine the changing landscape of deal structures, innovative licensing models, and successful case studies of strategic alliances. Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FiercePharma #BiotechPR #BiotechEvents

'Tis the season for AGMs and a point in the year to reflect and look ahead. For EuropaBio - the European Association for Bioindustries, the past year has seen a welcome amplification of biotechnology within policy makers' priorities and its recognition within legislation. A critical economic technology, NZIA, STEP, plus the arrival of a detailed Initiative 'Boosting biotech & biomanufacturing in the EU' which will shape the Commission to come. It's significance has also been recognised within legislative proposals, such as the #GPL, where the importance of incentivising and protecting biotech innovation improved a first draft from levels that would have driven innovation from the EU. The #NGT legislation also holds the promise of an empowered EU but with both files, there's a long way to go to ensure that Europe achieves its ambitions. EuropaBio achieves this with its Members, and we were delighted to welcome new faces to the Board, plus new company and association Members from across countries and sectors, reflecting the diversity and depth of biotechnology across sectors. We look ahead to a big year for biotech and thank all the people who help create the pathway with us.